Atherogenic effect of systemic lupus erythematosus pts blood serum
https://doi.org/10.14412/1995-4484-2003-1354
Abstract
Objective. To study relation of SLE pts blood serum atherogenicity to disease activity and corticosteroids (CS) administration. Methods. 40 young women with SLE were included. 20 of them did not received CS (group 1) and 20 were treated with small doses of CS (<15 mg/day) for a long time (group 2). Duration of the disease was longer in group 2 and SLEDAI indexes were higher in group 1. Control group consisted of 20 healthy women. Serum atherogenicity was examined in BALB/c mice peritoneal macrophages culture by accumulation of intracellular cholesterol (CH) induced by pts blood serum. Results. Most of pts blood serum (90%) and only 15% control blood serum possessed atherogenic potential causing 2-fold rise of intracellular cholesterol level. Frequency of serum atherogenic activity in pts having SLE for a long time was higher. Serum atherogenic activity in group 1 was higher than in group 2 (221±13% and 185±11 % respectively, p=0,044). Atherogenicity correlated with SLEDAI index (r=0,82, p=0,04). No correlation was found between atherogenicity and lipid fractions. Conclusion. Serum atherogenecity is directly dependent on disease activity what shows the significance of immunological changes in atherogenesis in SLE pts
References
1. <div><p>Маянский Ф.Н. Конденцнонирование нейтрофила. Успехи соврем, биолог., 1990, Т.104, вып. I, 90-105.</p><p>Тертов В.В. Множественно-модифицированные липо- протеиды низкой плотности, циркулирующие в крови человека. Ангиолог. сос.хирург., 1999, 5, 218-240.</p><p>Alarcon-Scgovia D. Pathogenesis of systemic lupus erythematosus: possible participation of antiphospholipid antibodies. lsr.J. Med. Sci., 1989, 25. 669-672.</p><p>Bennet R.M., Gabor G.T., Merritt M.J. DNA binding to human leukocytes: evidence for a receptor mediated association, internalization and degradation of DNA. J. Clin. Invest., 1985, 76, 2182-2188.</p><p>Frank M.M., Hamburger M.I., Lawley T.J.et al. Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N. Engl J Med., 1976, 300, 518-521.</p><p>Goldstein J.L., Ho G.K., Basu S.K., Brown M.S. Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc. Nat. Acad. Sci USA, 1979, 78, 333-337.</p><p>Kabakov A.E., Tertov V.V., Saenko V.A. The atherogenic effect of lupus sera: systemic lupus erythematosus-derived immune complexes stimulate the accumulation of cholesterol in cultured smooth muscle cells from human aorta. Clin. Immunol. Immunopathol., 1992, 62,3, 214-220.</p><p>Kabakov A.E., Saenko V.A., Poverenny A.M. LDL-medi- ated interacthion of DNA and DNA-anti-DNA immune complexes with cell surface. Clin. Exp. Immunol., 1991, 83, 357-363.</p><p>Kiener P., Rankin B. Davis P. et al. Immune complexes of LDL induce atherogenic responses in human monocytic cells. Arterioscler. Thromb. Vase. Biol., 1995, 15, 990-999.</p><p>Klimov A.N., Denisenko A.D., Vinogradov A.G. et al. Accumulation of cholesteryl esters in macrophages incubated with human lipoprotein-antibody autoimmune complex. Atherosclerosis, 1988. 74. 41-46.</p><p>Koffler D. Immunopathogenesis of systemic lupus erythematosus. Ann. Rev. Med., 1974, 25, 149-154.</p><p>Kostner G.M., Zechner R., Bihar-Varga M„ Gruber E. The interaction of human plasma LDL with glycosamino- glvcans: influence of the chemical composition. Lipids, 1985, 20, 24-29.</p><p>Lake R.A., Morgan A., Henderson B. et al. A key role for fibronectin in the sequential binding of native dsDNA and monoclonal anti-DNA antibodies to components of the extracellular matrix: its possible significance in glomerulonephritis. Immunology, 1985, 54, 389-395.</p><p>Lopes-Virella M.F., Virella G. Atherosclerosis and autoimmunity. Clin. Immunol. Immunopathol., 1994, 73, 2, 155167.</p><p>Parthasarathy S., Printz D., Boyd D. et al. Macrophage oxidation of low density lipoprotein generates a modified form recognized bY the scavenger receptor. Atherosclerosis, 1986, 6. 505-510.'</p><p>Ross R. Atherosclerosis - an inflammatory disease. New Engl. J. Med., 1999, 340, 115-126.</p><p>Schwartz C.J., Valente A.J., Spragut E.A. et al.: Monocyte-macrophage participation in atherogenesis: Inflammatory components of pathogenesis. Semin. Thromb. Hemost., 1986, 12,79-86.</p><p>Smeenk R., Lelij G., Aarden L. Avidity of antibodies to dsDNA: comparison 1FT on Crithidia luciliae. Farr assay and PEG assay. J. Immunol., 1982 b, 128, 73-81.</p><p>Tan E.N., Cohen A.S., Fries J.F. et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr. Rheum., 1982, 25, 1271.</p><p>Tertov V.V., Orekhov A.N., Nikitina N.A. et al. Peritoneal macrophages: a model for detecting atherogenic potential in patients’ blood serum. Ann. Med., 1989, 21 (6), 455-459.</p><p>Tertov V.V., Orekhov A.N., Ryong L.N., Smirnov V.N. Intracellular cholesterol accumulation is accompanied by enhanced proliferative activity of human aortic intimal cell. Tissue Cell, 1988, 20. 849-851.</p></div><br />
Review
For citations:
Alekberova Z.S., Gerasimova E.V., Sobenin I.A. Atherogenic effect of systemic lupus erythematosus pts blood serum. Rheumatology Science and Practice. 2003;41(3):21-23. (In Russ.) https://doi.org/10.14412/1995-4484-2003-1354
Views:
2369
Email this article 